Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
KPTI Stock Chart & Stats
$6.08
-$0.04(-5.28%)
At close: 4:00 PM EST
$6.08
-$0.04(-5.28%)
Day’s Range― - ―
52-Week Range$3.51 - $16.96
Previous CloseN/A
Volume220.82K
Average Volume (3M)228.24K
Market Cap
$54.89M
Enterprise Value$176.07M
Total Cash (Recent Filing)$38.73M
Total Debt (Recent Filing)$94.80M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Nov 03, 2025EPS Estimate
-3.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.32
Shares Outstanding8,671,278
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.21
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit1.33
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$12.80Price Target Upside110.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Trial DevelopmentsInvestors' sights are on the top-line Phase 3 SENTRY trial results, expected to show promising outcomes based on previous Phase 1 results.
Market Launch PotentialThere is potential for a rapid launch in myelofibrosis, supported by high physician interest in adopting combination therapy.
Strategic FinancingStrategic financing and capital structure transactions provide $100M in financial flexibility, extending the operational cash runway into 2Q26.
Bears Say
Cash Flow ConcernsThe company is working under a constrained cash runway.
Revenue GuidanceFull-year guidance for Xpovio revenues was lowered.
Stock Valuation OutlookThe company's price target is lowered to $6 from $8, suggesting a less optimistic outlook on stock valuation.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.51 and its highest was $16.96 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $54.89M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Nov 03, 2025 which is in 3 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 11, 2025. The company reported -$4.32 earnings per share for the quarter, missing the consensus estimate of -$4.082 by -$0.238.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -3.47.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 8,671,278 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$4.32 in its last earnings report, missing expectations of -$4.082. Following the earnings report the stock price went down -4.315%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.80 (110.53% Upside)
$12.80 (110.53% Upside)
Hedge Fund Trend
Decreased
By 8.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.99%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (KPTI) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of cancer and other serious diseases. The company focuses on leveraging its proprietary SINE compound technology platform to develop oral drugs that inhibit the nuclear export of proteins, thereby targeting key pathways involved in various malignancies. Karyopharm's core product candidates include Xpovio (selinexor), an FDA-approved treatment for multiple myeloma and certain types of lymphoma, along with a robust pipeline of investigational therapies aimed at diverse oncology indications.
KPTI Company Deck
KPTI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in clinical trials and commercial performance, especially with a steady increase in revenue from XPOVIO and global expansion efforts. However, significant financial challenges due to a net loss, decline in total revenue, and approaching debt maturity are concerning. The company is actively working on strategic alternatives to enhance liquidity.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$12.80
▲(110.53% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
4.93% Insiders
39.40% Mutual Funds
<0.01% Other Institutional Investors
51.96% Public Companies and
Individual Investors